Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Managing dual antiplatelet therapy (DAPT) perioperatively is challenging, especially in patients who have recently undergone percutaneous coronary intervention (PCI). Intravenous antiplatelet agents are recommended in these cases. This case series describes the perioperative management of two high bleeding risk patients with recent PCI undergoing cardiac and non-cardiac surgeries using cangrelor monotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5543/tkda.2024.86987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cangrelor Monotherapy Bridging for Cardiac and Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Turk Kardiyol Dern Ars
March 2025
First Cardiology Department, AHEPA General University Hospital, Aristotle University of Thessaloniki, Greece.
Managing dual antiplatelet therapy (DAPT) perioperatively is challenging, especially in patients who have recently undergone percutaneous coronary intervention (PCI). Intravenous antiplatelet agents are recommended in these cases. This case series describes the perioperative management of two high bleeding risk patients with recent PCI undergoing cardiac and non-cardiac surgeries using cangrelor monotherapy.
View Article and Find Full Text PDFThe chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.
BMC Med
December 2024
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Cangrelor for emergent carotid stenting during stroke thrombectomy: a comparative analysis versus glycoprotein IIb/IIIa inhibitors or aspirin monotherapy.
J Neurointerv Surg
June 2025
Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Background: Periprocedural antiplatelet treatment is a key determinant for the risk-benefit balance of emergent carotid artery stenting (eCAS) during stroke endovascular treatment (EVT). We aimed to assess the safety and efficacy profile of cangrelor compared with glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors or aspirin monotherapy.
Methods: Data were extracted from the Endovascular Treatment in Ischemic Stroke (ETIS) registry, a prospective nationwide observational registry of stroke EVT in France.
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
N Engl J Med
September 2017
From the Department of Cardiology, Clinical Sciences, Lund University, Lund (D.E., P.B., A.L., T.T., M.G., F.S., S.K.), the Department of Cardiology, Sahlgrenska University Hospital, Gothenburg (E.O., D.I., T.R., O.A.), the Department of Cardiology, Faculty of Health, Örebro University, Örebro (O.
Background: The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.
Methods: In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access.
Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Vasc Health Risk Manag
February 2017
Department of Pharmacy Practice, MCPHS University, Boston, MA, USA.
This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease activator receptor-1, which prevents thrombin from activating platelets. Two Phase III clinical trials and multiple subanalyses from the two trials with vorapaxar have been published.
View Article and Find Full Text PDF